Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Myeloma: The First Remission Is the Deepest

October 26th 2020

Not everyone with myeloma needs to be treated right away, but when they do, there are some important upfront considerations for patients and providers.

Program Leads Patients With Cancer on ‘The Right Track’

September 24th 2020

Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Drug Exposure, Disease Characteristics Not Linked to Increased Mortality Risk in Patients with Multiple Myeloma Who Contracted COVID-19

September 17th 2020

Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.

Phase 3 TOURMALINE-MM2 Study Fails to Meet Primary Endpoint in Treating Newly Diagnosed Multiple Myeloma

September 14th 2020

The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.

Drug Conjugate Designed to Deliver Iodine-131 Shows Promise in Triple-Refractory Multiple Myeloma

September 11th 2020

Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

Velcade-Based Triplet Regimen ‘Should Remain’ Standard of Care in Newly Diagnosed Multiple Myeloma

September 10th 2020

When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

The Latest FDA Approvals and Updates Patients with Cancer May Have Missed

September 9th 2020

There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

FDA Grants Priority Review to Melflufen-Dexamethasone Combination for Multiple Myeloma

September 4th 2020

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

Ninlaro Found to Be Effective and Safe for Treatment of Newly Diagnosed Multiple Myeloma

August 28th 2020

In addition to improving progression-free survival, researchers have found single-agent Ninlaro (ixazomib) to be a tolerable option in patients with newly diagnosed multiple myeloma who have also already undergone an autologous stem cell transplant.

Resources from the MMRF

August 26th 2020

Supportive Care Options for Patients with Multiple Myeloma

August 26th 2020

Hope for Relapsed/Refractory Multiple Myeloma

August 26th 2020

Options for Newly Diagnosed Multiple Myeloma

August 26th 2020

Understanding Smoldering Multiple Myeloma

August 26th 2020

FDA Approves Kyprolis in Combination with Darzalex and Dexamethasone for Relapsed/Refractory Multiple Myeloma

August 20th 2020

The Food and Drug Administration (FDA) has approved the expansion of Kyprolis (carfilzomib) in combination to with Darzalex (daratumumab) plus dexamethasone in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma who have received a maximum of three prior lines of therapy.

More Effective Treatment Options are Needed for Patients with Advanced Multiple Myeloma

August 20th 2020

Despite recent advances in the treatment of multiple myeloma, more must be done to find effective treatment options for patients with advanced disease, according to Dr. Luciano J. Costa.

Clinical Trials Are Pivotal in the Evolution of CAR-T Cell Therapy in Multiple Myeloma

August 18th 2020

While the use of CAR-T cell therapy is currently still being investigated in patients with multiple myeloma, Dr. Nina Shah of the UCSF Helen Diller Family Comprehensive Cancer Center believes that these clinical trials will be what ultimately moves the field forward.

An Expert Discusses the Future of Multiple Myeloma Treatments

August 18th 2020

The future of multiple myeloma is heading toward combination therapies and CAR-T cell treatments, according to Dr. Betsy O'Donnell.

What Do You Do to Pamper Yourself During or After Cancer Treatment?

August 17th 2020

On social media, CURE® recently asked its readers to share how they pamper and treat themselves during or after their cancer treatment. Here, we share some of their responses.

FDA Approves Blenrep to Treat Relapsed/Refractory Multiple Myeloma

August 6th 2020

The Food and Drug Administration approved Blenrep to treat patients with relapsed/refractory multiple myeloma.

What Advice Would You Give Someone Looking to Help A Friend or Loved One with Cancer?

August 4th 2020

On social media, CURE® recently asked its readers to share the advice they would give someone looking to help a friend or loved one with cancer. Here, we share some of their responses.

Minimal Residual Disease is A Vital Marker for Patients with Multiple Myeloma, Says Expert

July 31st 2020

Dr. Parameswaran Hari discusses the importance of understanding a patient’s MRD if they are receiving the maintenance therapy Sarclisa for multiple myeloma.

Early Mobility Program For Patients With Cancer Helps to Maintain or Improve Their Mobility

July 29th 2020

The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.

Higher Body Weight Associated with Slightly Improved Survival Outcomes in Patients with Multiple Myeloma

July 24th 2020

Patients with multiple myeloma who were obese or overweight had a trend toward slightly improved progression-free survival and overall survival outcomes compared to patients who had a normal weight, according to data from an exploratory analysis.

The Latest News and Updates in Multiple Myeloma

July 21st 2020

A roundup of the latest news and updates for patients with multiple myeloma from CURE®.

First-in-Human Trial of Novel CAR T-Cell Product for Treatment of Relapsed/Refractory Multiple Myeloma Halted After Patient Dies

July 15th 2020

The manufacturer is working with the Food and Drug Administration to address any requests including changes to the protocol of the MELANI-01 trial to enhance patient safety.

FDA Panel Unanimously Supports Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma

July 15th 2020

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.

Patients with Multiple Myeloma Who Join MMRF's CureCloud May Improve Their Treatment Options While Contributing to Research

July 15th 2020

The Multiple Myeloma Research Foundation’s newly launched CureCloud is a registry designed to collect clinical and genomic information about patients. Its goals are to help researchers discover treatments for various subtypes of the disease and let patients know whether they have any of 70 genetic aberrations associated with myeloma.

Saying Goodbye

June 20th 2020

Novel CAR-T Cell Therapy Shows Promise in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

June 16th 2020

After a median follow-up of 13.3 months, the median overall response rate across all patients who received idecabtagene vicleucel (ide-cel) was 73%, including a complete response of 33%.